Akebia Therapeutics (AKBA) Leases (2019 - 2025)
Historic Leases for Akebia Therapeutics (AKBA) over the last 7 years, with Q3 2025 value amounting to $4.8 million.
- Akebia Therapeutics' Leases fell 4798.92% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 4798.92%. This contributed to the annual value of $8.2 million for FY2024, which is 3381.12% down from last year.
- Akebia Therapeutics' Leases amounted to $4.8 million in Q3 2025, which was down 4798.92% from $6.0 million recorded in Q2 2025.
- Akebia Therapeutics' 5-year Leases high stood at $33.9 million for Q4 2021, and its period low was $4.8 million during Q3 2025.
- Its 5-year average for Leases is $18.7 million, with a median of $14.4 million in 2023.
- In the last 5 years, Akebia Therapeutics' Leases skyrocketed by 3080.8% in 2022 and then crashed by 5922.81% in 2024.
- Over the past 5 years, Akebia Therapeutics' Leases (Quarter) stood at $33.9 million in 2021, then decreased by 13.87% to $29.2 million in 2022, then tumbled by 57.42% to $12.4 million in 2023, then crashed by 33.81% to $8.2 million in 2024, then tumbled by 41.14% to $4.8 million in 2025.
- Its Leases stands at $4.8 million for Q3 2025, versus $6.0 million for Q2 2025 and $7.1 million for Q1 2025.